These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 25712263)

  • 1. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
    Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
    Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
    Gu JJ; Hernandez-Ilizaliturri FJ; Kaufman GP; Czuczman NM; Mavis C; Skitzki JJ; Czuczman MS
    Br J Haematol; 2013 Sep; 162(5):657-69. PubMed ID: 23826755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.
    Barth MJ; Hernandez-Ilizaliturri FJ; Mavis C; Tsai PC; Gibbs JF; Deeb G; Czuczman MS
    Br J Haematol; 2012 Feb; 156(4):490-8. PubMed ID: 22150234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
    Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK
    Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
    Jóna A; Khaskhely N; Buglio D; Shafer JA; Derenzini E; Bollard CM; Medeiros LJ; Illés A; Ji Y; Younes A
    Exp Hematol; 2011 Oct; 39(10):1007-1017.e1. PubMed ID: 21767511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.
    Shimizu R; Kikuchi J; Wada T; Ozawa K; Kano Y; Furukawa Y
    Leukemia; 2010 Oct; 24(10):1760-8. PubMed ID: 20686505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis.
    Shi W; Han X; Yao J; Yang J; Shi Y
    Leuk Res; 2012 Jun; 36(6):749-55. PubMed ID: 22475365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
    Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs.
    Vega MI; Martinez-Paniagua M; Jazirehi AR; Huerta-Yepez S; Umezawa K; Martinez-Maza O; Bonavida B
    Leuk Lymphoma; 2008 Oct; 49(10):1982-94. PubMed ID: 18949621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models.
    Gu JJ; Hernandez-Ilizaliturri FJ; Mavis C; Czuczman NM; Deeb G; Gibbs J; Skitzki JJ; Patil R; Czuczman MS
    Anticancer Drugs; 2013 Nov; 24(10):1030-8. PubMed ID: 23995855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cells.
    Gu JJ; Kaufman GP; Mavis C; Czuczman MS; Hernandez-Ilizaliturri FJ
    Oncotarget; 2017 Feb; 8(8):12741-12753. PubMed ID: 28055975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas.
    Brem EA; Thudium K; Khubchandani S; Tsai PC; Olejniczak SH; Bhat S; Riaz W; Gu J; Iqbal A; Campagna R; Knight J; Mavis C; Hoskin P; Deeb G; Gibbs JF; Fetterly G; Czuczman MS; Hernandez-Ilizaliturri FJ
    Br J Haematol; 2011 Jun; 153(5):599-611. PubMed ID: 21492126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
    Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
    [No Abstract]   [Full Text] [Related]  

  • 15. TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.
    Simmons JK; Patel J; Michalowski A; Zhang S; Wei BR; Sullivan P; Gamache B; Felsenstein K; Kuehl WM; Simpson RM; Zingone A; Landgren O; Mock BA
    Mol Oncol; 2014 Mar; 8(2):261-72. PubMed ID: 24429254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
    Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
    J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells.
    Wang B; Lyu H; Pei S; Song D; Ni J; Liu B
    Cell Cycle; 2018; 17(8):985-996. PubMed ID: 29969371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
    Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
    Czuczman MS; Olejniczak S; Gowda A; Kotowski A; Binder A; Kaur H; Knight J; Starostik P; Deans J; Hernandez-Ilizaliturri FJ
    Clin Cancer Res; 2008 Mar; 14(5):1561-70. PubMed ID: 18316581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.